Evidence map›Paper›PMID 40620793›Full record

ArticleFrontiers in endocrinology2025

Age-stratified anti-Müllerian hormone (AMH) nomogram: a comprehensive cohort study including 22.920 women.

Kiper Aslan, Isil Kasapoglu, Bahadir Kosan, Aylin Tunali, Ilayda Tellioglu, Gurkan Uncu

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kiper AslanDepartment of Obstetrics and Gynecology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
Isil KasapogluDepartment of Obstetrics and Gynecology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
Bahadir KosanDepartment of Obstetrics and Gynecology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
Aylin TunaliDepartment of Obstetrics and Gynecology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
Ilayda TelliogluDepartment of Obstetrics and Gynecology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
Gurkan UncuDepartment of Obstetrics and Gynecology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infertility rates have been rising globally, necessitating accurate assessment tools for ovarian reserve. Anti-Müllerian hormone (AMH) is a key biomarker for evaluating ovarian reserve, yet age-stratified reference data remain limited. Establishing an AMH nomogram could enhance fertility counseling and treatment planning. Objective: To develop an age-stratified AMH nomogram to improve the understanding of ovarian reserve across reproductive ages and assist in comparing individual AMH values with age-specific thresholds, aiding in the baseline infertility work-up. Methods: This retrospective cohort study analyzed AMH test results from a tertiary university hospital's electronic database between April 2015 and June 2024. Data were collected from various departments, excluding women younger than 18 or older than 45 years. Median AMH levels and interquartile ranges were calculated for each age group. The prevalence of diminished ovarian reserve (DOR), defined as AMH <1.2 ng/mL, was determined. Statistical analyses, including correlation testing and subgroup comparisons across different clinical settings, were performed using SPSS version 22 (IBM Corp., Armonk, NY, USA). Results: A total of 22,920 AMH results were analyzed after excluding patients outside the 18-45 age range and those with incomplete data. More than half of the AMH tests were from women aged 24-33 years. The results demonstrated a significant negative correlation between age and AMH levels, with a median AMH value dropping below 1.2 ng/mL by age 36. The prevalence of DOR increased from 15.9% at age 18 to 96% at age 45. Additionally, women from the Endometriosis Unit had significantly lower AMH levels (median 1.6 ng/mL) compared to other departments (median 2.03 ng/mL). The age-stratified AMH distribution remained consistent even when patients from ART (Assisted Reproductive Technology) centers, REI (Reproductive Endocrinology and Infertility), and the Endometriosis Unit were excluded. Conclusion: This study provides an age-stratified AMH nomogram that can serve as a valuable tool for clinicians to assess ovarian reserve more accurately. The sharp decline in AMH levels, particularly after age 36, emphasizes the need for timely fertility evaluations and interventions, particularly in populations at risk for diminished ovarian reserve, such as those with endometriosis.

Indexed as

Anti-Mullerian HormoneInfertility, FemaleNomogramsOvarian ReserveAdolescentAdultAge FactorsBiomarkersCohort StudiesFemaleHumansMiddle AgedRetrospective StudiesYoung AdultAnti-Mullerian HormoneBiomarkersage stratificationAMHdiminished ovarian reserveendometriosisinfertilitynomogramovarian reserve

Identifiers

PMID40620793
PMCPMC12226283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.